
Fabiana D V Genvigir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5799608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CYP3A5âŽ3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clinica Chimica Acta, 2008, 398, 15-20.	0.5	54
2	Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenetics and Genomics, 2016, 26, 462-472.	0.7	33
3	Influence of <i><scp>ABCC</scp>2, <scp>CYP</scp>2C8</i> , and <i><scp>CYP</scp>2J2</i> Polymorphisms on Tacrolimus and Mycophenolate Sodium–Based Treatment in Brazilian Kidney Transplant Recipients. Pharmacotherapy, 2017, 37, 535-545.	1.2	31
4	Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Clinica Chimica Acta, 2010, 411, 631-637.	0.5	29
5	Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clinica Chimica Acta, 2008, 389, 79-86.	0.5	21
6	Differentially expressed urinary exo-miRs and clinical outcomes in kidney recipients on short-term tacrolimus therapy: a pilot study. Epigenomics, 2020, 12, 2019-2034.	1.0	13
7	ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells. Drug Metabolism and Drug Interactions, 2011, 26, 33-6.	0.3	10
8	<i>ABCA1</i> expression and statins: inhibitory effect in peripheral blood mononuclear cells. Pharmacogenomics, 2009, 10, 997-1005.	0.6	8
9	Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Lipids in Health and Disease, 2011, 10, 206.	1.2	8
10	Differentiation of African Components of Ancestry to Stratify Groups in a Case–Control Study of a Brazilian Urban Population. Genetic Testing and Molecular Biomarkers, 2012, 16, 524-530.	0.3	5
11	Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. Molecular Diagnosis and Therapy, 2021, 25, 735-755.	1.6	3
12	Pharmacogenomics of Antihypertensive Drugs in Brazil: Recent Progress and Clinical Implications. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 1263-1275.	0.6	1